Synonym
MK-410; MK 410; MK410
IUPAC/Chemical Name
2-(5-methoxy-2-methyl-1-(4-(methylthio)benzyl)-1H-indol-3-yl)propanoic acid
InChi Key
QTUGRCJHUSVWGW-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H23NO3S/c1-13(21(23)24)20-14(2)22(12-15-5-8-17(26-4)9-6-15)19-10-7-16(25-3)11-18(19)20/h5-11,13H,12H2,1-4H3,(H,23,24)
SMILES Code
O=C(O)C(C)C1=C(C)N(CC2=CC=C(SC)C=C2)C3=C1C=C(OC)C=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
369.48
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Van Dyke K, Peden D, Van Dyke C, Jones G, Castranova V, Ma J. Inhibition by nonsteroidal antiinflammatory drugs of luminol-dependent human-granulocyte chemiluminescence and [3H]FMLP binding. Effect of sulindac sulfide, indomethacin metabolite, and optical enantiomers (+) and (-) MK830. Inflammation. 1982 Mar;6(1):113-25. PubMed PMID: 7085041.
2: Lassmann G, Curtis J, Liermann B, Mason RP, Eling TE. ESR studies on reactivity of protein-derived tyrosyl radicals formed by prostaglandin H synthase and ribonucleotide reductase. Arch Biochem Biophys. 1993 Jan;300(1):132-6. PubMed PMID: 8380961.
3: Hart DA, Mannerfeldt J, Babins E. Treatment of mice with indomethacin leads to the appearance of a 125,000 dalton plasma protein with the characteristics of an acute phase reactant. J Clin Lab Immunol. 1987 Jun;23(2):83-90. PubMed PMID: 2442392.
4: Markey CM, Alward A, Weller PE, Marnett LJ. Quantitative studies of hydroperoxide reduction by prostaglandin H synthase. Reducing substrate specificity and the relationship of peroxidase to cyclooxygenase activities. J Biol Chem. 1987 May 5;262(13):6266-79. PubMed PMID: 3106353.
5: Hart DA. Indomethacin induces the suppression of plasma neutral proteinase activity in mice: possible relationship to efficacy as an anti-inflammatory drug and induction of alterations in the immune system. J Clin Lab Immunol. 1986 Aug;20(4):199-205. PubMed PMID: 3020255.
6: Sato T, Ohtani Y, Yamada Y, Saitoh S, Harada H. Difference in the metabolism of vitamin K between liver and bone in vitamin K-deficient rats. Br J Nutr. 2002 Apr;87(4):307-14. PubMed PMID: 12064340.
